1-5 of 5
Byron Hann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition

Gary K. Scott, Christina Yau, Beatrice C. Becker, Sana Khateeb, Sophia Mahoney, Martin Borch Jensen, Byron Hann, Bryan J. Cowen, Scott D. Pegan, Christopher C. Benz
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (8): 1374–1385.
https://doi.org/10.1158/1535-7163.MCT-18-1323
Published: 01 August 2019
View article titled, Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
Open the PDF for Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition in another window
Includes: Multimedia, Supplementary data
Journal Articles

A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors

Chester E. Chamberlain, Michael S. German, Katherine Yang, Jason Wang, Henry VanBrocklin, Melanie Regan, Kevan M. Shokat, Gregory S. Ducker, Grace E. Kim, Byron Hann, David B. Donner, Robert S. Warren, Alan P. Venook, Emily K. Bergsland, Danny Lee, Yucheng Wang, Eric K. Nakakura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (12): 2702–2709.
https://doi.org/10.1158/1535-7163.MCT-17-1204
Published: 03 December 2018
View article titled, A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors
Open the PDF for A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract C61: Non-homogeneous drug penetrance of veliparib measured in triple negative breast tumors

Imke H. Bartelink, Brendan Prideaux, Gregor Krings, Lisa Wilmes, Pei R.E. Lee, Byron Hann, Jean-Philippe Coppé, Diane Heditsian, Lamorna Swigart-Brown, Ella F. Jones, Sergey Magnitsky, Ron Keizer, Laura Esserman, Weiming Ruan, Alan Wu, Douglas Yee, Veronique Dartois, Denise Wolf, Rada Savic, Laura vantVeer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C61.
https://doi.org/10.1158/1535-7163.TARG-15-C61
Published: 01 December 2015
View article titled, Abstract C61: Non-homogeneous drug penetrance of veliparib measured in triple negative breast tumors
Journal Articles

Validation of the Hsp70–Bag3 Protein–Protein Interaction as a Potential Therapeutic Target in Cancer

Xiaokai Li, Teresa Colvin, Jennifer N. Rauch, Diego Acosta-Alvear, Martin Kampmann, Bryan Dunyak, Byron Hann, Blake T. Aftab, Megan Murnane, Min Cho, Peter Walter, Jonathan S. Weissman, Michael Y. Sherman, Jason E. Gestwicki
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (3): 642–648.
https://doi.org/10.1158/1535-7163.MCT-14-0650
Published: 09 March 2015
View article titled, Validation of the Hsp70–Bag3 Protein–Protein Interaction as a Potential Therapeutic Target in Cancer
Open the PDF for Validation of the Hsp70–Bag3 Protein–Protein Interaction as a Potential Therapeutic Target in Cancer in another window
Includes: Supplementary data
Journal Articles

Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma

Olga K. Mirzoeva, Eric A. Collisson, Peter M. Schaefer, Byron Hann, Yun K. Hom, Andrew H. Ko, W. Michael Korn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (10): 2213–2225.
https://doi.org/10.1158/1535-7163.MCT-13-0104
Published: 07 October 2013
View article titled, Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Open the PDF for Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma in another window
Includes: Supplementary data